kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2014-4-95-103kpccz-91Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУГЕПАРИН-ИНДУЦИРОВАННАЯ ТРОМБОЦИТОПЕНИЯ ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ВМЕШАТЕЛЬСТВАХ. МЕХАНИЗМЫ РАЗВИТИЯ, ДИАГНОСТИКИ И МЕТОДЫ КОРРЕКЦИИHEPARIN INDUCED THROMBOCYTOPENIA IN CARDIOVASCULAR SURGERY. PATHOGENESIS, DIAGNOSTICS AND CORRECTION METHODSПироговА. Л.PirogovA. L.

доктор медицинских наук

заведующий приемным отделением, главный внештатный кардиолог

Адрес для переписки:А. Л. Пирогов, 454003, г. Челябинск, пр. Героя России Родионова Е. Н., д. 2. Тел: +7(351) 255-93-67

Dr. Med. Sci.

chief freelance cardiologist

Correspondence address:A. L. Pirogov, 2, Hero of Russia E. N. Rodionov Pr., 454003, Chelyabinsk. Tel.: +7(351) 255-93-67

kardio74@mail.ruФедеральное государственное бюджетное учреждение «Федеральный центр сердечно-сосудистой хирургии» Министерства здравоохранения Российской Федерации, ЧелябинскРоссияFederal State Budgetary Institution Federal Cardiovascular Surgery Centre, Ministry of Healthcare of the Russian Federation, ChelyabinskRussian Federation2014020720150495103Copyright © Пирогов А.Л., 20152015Пирогов А.Л.Pirogov A.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/91

В статье представлен обзор литературы, посвященный проблеме развития такого грозного осложнения, как гепарин-индуцированная тромбоцитопения, клинике, способам ее диагностики и современной тактике ведения такого рода пациентов при выполнении лечебно-диагностических мероприятий при сердечно-сосудистых заболеваниях.

The article presents the review of the literature dedicated to the problem of pathogenesis of such a severe complication as the heparin induced thrombocytopenia, clinical implications, methods of its diagnostics and modern management of such patients when performing treatment and diagnostic measures in cardiovascular diseases.

гепарин-индуцированная тромбоцитопенияклиникадиагностикалечениерекомендацииheparin induced thrombocytopeniaclinical implicationsdiagnosticstreatmentrecommendationsReferencesБокерия Л . А ., Чигерин И . Н. Гепарининдуцированная тромбоцитопения (современное состояние проблемы). М.: Изд. НЦССХ им. А. Н. Бакулева, 2007. 96 с.Бокерия Л . А ., Чигерин И . Н. Гепарининдуцированная тромбоцитопения (современное состояние проблемы). М.: Изд. НЦССХ им. А. Н. Бакулева, 2007. 96 с.Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery / J. C. Vasquez [et al.] // Ann. Thorac. Surg. 2002. Vol. 74 (6). P. 2177–2179.Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery / J. C. Vasquez [et al.] // Ann. Thorac. Surg. 2002. Vol. 74 (6). P. 2177–2179.Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance / P. Eichler [et al.] // Blood. 2000. Vol. 96 (7). P. 2373–2378.Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance / P. Eichler [et al.] // Blood. 2000. Vol. 96 (7). P. 2373–2378.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin / T. E. Warkentin [et al.] // Blood. 2005. Vol. 106 (12). P. 3791–3796.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin / T. E. Warkentin [et al.] // Blood. 2005. Vol. 106 (12). P. 3791–3796.Arepally G. M., Ortel T. L. Clinical practice. Heparininduced thrombocytopenia // N. Engl. J. Med. 2006. Vol. 355 (8). P. 809–817.Arepally G. M., Ortel T. L. Clinical practice. Heparininduced thrombocytopenia // N. Engl. J. Med. 2006. Vol. 355 (8). P. 809–817.Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Circulation. 2001. Vol. 103 (14). P. 1838–1843Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Circulation. 2001. Vol. 103 (14). P. 1838–1843Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Catheter Cardiovasc. Interv. 2002. Vol. 57 (2). P. 177–184.Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Catheter Cardiovasc. Interv. 2002. Vol. 57 (2). P. 177–184.Argatroban anticoagulation in patients with heparininduced thrombocytopenia / B. E. Lewis // Arch. Intern. Med. 2003. Vol. 163 (15). P. 1849–1856.Argatroban anticoagulation in patients with heparininduced thrombocytopenia / B. E. Lewis // Arch. Intern. Med. 2003. Vol. 163 (15). P. 1849–1856.Benefit-risk assessment of treatments for heparin-induced thrombocytopenia / Messmore H. [et al.] // Drug Saf. 2003. Vol. 26 (9). P. 625–41.Benefit-risk assessment of treatments for heparin-induced thrombocytopenia / Messmore H. [et al.] // Drug Saf. 2003. Vol. 26 (9). P. 625–41.Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention / K. R. Campbell [et al.] // J. Invasive Cardiol. 2000. Vol. 12 (Suppl. F. 14).Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention / K. R. Campbell [et al.] // J. Invasive Cardiol. 2000. Vol. 12 (Suppl. F. 14).Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass / A. Koster [et al.] // Anesth. Analg. 2003. Vol. 96 (2). P. 383–386 (table of contents).Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass / A. Koster [et al.] // Anesth. Analg. 2003. Vol. 96 (2). P. 383–386 (table of contents).Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature / I. Datta [et al.] // J. Trauma Manag. Outcomes. 2010. Vol. 4 (1).Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature / I. Datta [et al.] // J. Trauma Manag. Outcomes. 2010. Vol. 4 (1).Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparininduced thrombocytopenia / C. Pouplard [et al.] // Am. J. Clin. Pathol. 1999. Vol. 111 (5). P. 700–706.Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparininduced thrombocytopenia / C. Pouplard [et al.] // Am. J. Clin. Pathol. 1999. Vol. 111 (5). P. 700–706.Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass / A. Lillo-Le Louët [et al.] // J. Thromb. Haemost. 2004. Vol. 2 (11). P. 1882–1888.Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass / A. Lillo-Le Louët [et al.] // J. Thromb. Haemost. 2004. Vol. 2 (11). P. 1882–1888.Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values / R. C. Gosselin [et al.] // Am. J. Clin. Pathol. 2004. Vol. 121 (4). P. 593–599.Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values / R. C. Gosselin [et al.] // Am. J. Clin. Pathol. 2004. Vol. 121 (4). P. 593–599.Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Chest. 2006. Vol. 129 (6) P. 1407–1416.Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia / B. E. Lewis [et al.] // Chest. 2006. Vol. 129 (6) P. 1407–1416.Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia / B. Tardy-Poncet [et al.] // Chest. 1999. Vol. 115 (6). P. 1616–1620.Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia / B. Tardy-Poncet [et al.] // Chest. 1999. Vol. 115 (6). P. 1616–1620.Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia / T. H. Kiser [et al.] // Pharmacotherapy. 2005. Vol. 25 (12). P. 1736–1745.Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia / T. H. Kiser [et al.] // Pharmacotherapy. 2005. Vol. 25 (12). P. 1736–1745.Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia / B. Lobo [et al.] // Thromb. Haemost. 2008. Vol. 99 (1). P. 208–214.Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia / B. Lobo [et al.] // Thromb. Haemost. 2008. Vol. 99 (1). P. 208–214.Fondaparinux thromboprophylaxis-associated heparininduced thrombocytopenia syndrome complicated by arterial thrombotic stroke / M. Salem [et al.] // Thromb. Haemost. 2010. Vol. 104 (5). P. 10711072.Fondaparinux thromboprophylaxis-associated heparininduced thrombocytopenia syndrome complicated by arterial thrombotic stroke / M. Salem [et al.] // Thromb. Haemost. 2010. Vol. 104 (5). P. 10711072.Gallus A. S., Coghlan D. W. Heparin pentasaccharide // Curr. Opin. Hematol. 2002. Vol. 9 (5). P. 422–429.Gallus A. S., Coghlan D. W. Heparin pentasaccharide // Curr. Opin. Hematol. 2002. Vol. 9 (5). P. 422–429.GEHT-HIT StudyGroup. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin / B. Tardy [et al.] // Blood. 2006. Vol. 108 (5). P. 1492–1496.GEHT-HIT StudyGroup. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin / B. Tardy [et al.] // Blood. 2006. Vol. 108 (5). P. 1492–1496.Gender imbalance and risk factor interaction in heparininduced thrombocytopenia / T. E. Warkentin [et al.] // Blood. 2006. Vol. 108 (9). P. 2937–2941.Gender imbalance and risk factor interaction in heparininduced thrombocytopenia / T. E. Warkentin [et al.] // Blood. 2006. Vol. 108 (9). P. 2937–2941.Greinacher A., Lubenow N., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia // Circulation. 2003. Vol. 108 (17). P. 2062–2065.Greinacher A., Lubenow N., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia // Circulation. 2003. Vol. 108 (17). P. 2062–2065.Greinacher A., Warkentin T. E. Heparin-induced thrombocytopenia. New York, N. Y: Marcel Dekker, 2004. 627 р.Greinacher A., Warkentin T. E. Heparin-induced thrombocytopenia. New York, N. Y: Marcel Dekker, 2004. 627 р.Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen / A. Greinacher [et al.] // Thromb. Haemost. 1994. Vol. 71 (2). P. 247–251.Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen / A. Greinacher [et al.] // Thromb. Haemost. 1994. Vol. 71 (2). P. 247–251.Heparin-induced thrombocytopenia / D. B. Brieger [et al.] // J. Am. Coll. Cardiol. 1998. Vol. 31 (7). P. 1449–1459.Heparin-induced thrombocytopenia / D. B. Brieger [et al.] // J. Am. Coll. Cardiol. 1998. Vol. 31 (7). P. 1449–1459.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin / T. E. Warkentin [et al.] // N. Engl. J. Med. 1995. Vol. 332 (20). P. 1330–1335.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin / T. E. Warkentin [et al.] // N. Engl. J. Med. 1995. Vol. 332 (20). P. 1330–1335.Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy / E. A. Natelson [et al.] // Ann. Intern. Med. 1969. Vol. 71 (6). P. 1121–1125.Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy / E. A. Natelson [et al.] // Ann. Intern. Med. 1969. Vol. 71 (6). P. 1121–1125.Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes / A. Greinacher [et al.] // J. Thromb. Haemost. 2007. Vol. 5 (8). P. 1666–1673.Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes / A. Greinacher [et al.] // J. Thromb. Haemost. 2007. Vol. 5 (8). P. 1666–1673.http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20883s4lbl.pdf.http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20883s4lbl.pdf.http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf.http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf.Ibbotson T., Perry C. M. Danaparoid: a review of its use in thromboembolic and coagulation disorders // Drugs. 2002. Vol. 62 (15). P. 2283–2314.Ibbotson T., Perry C. M. Danaparoid: a review of its use in thromboembolic and coagulation disorders // Drugs. 2002. Vol. 62 (15). P. 2283–2314.IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics / S. Motokawa [et al.] // BMC. Musculoskelet Disord. 2011. Vol. 12 (22).IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics / S. Motokawa [et al.] // BMC. Musculoskelet Disord. 2011. Vol. 12 (22).Impact of the patient population on the risk for heparininduced thrombocytopenia / T. E. Warkentin [et al.] // Blood. 2000. Vol. 96 (5). P. 1703–1708.Impact of the patient population on the risk for heparininduced thrombocytopenia / T. E. Warkentin [et al.] // Blood. 2000. Vol. 96 (5). P. 1703–1708.Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations / S. D. Gitlin [et al.] // J. Vasc. Surg. 1998. Vol. 27 (3). P. 568–575.Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations / S. D. Gitlin [et al.] // J. Vasc. Surg. 1998. Vol. 27 (3). P. 568–575.Jang I. K., Hursting M. J. When heparins promote thrombosis: review of heparin-induced thrombocytopenia // Circulation. 2005. Vol. 111 (20). P. 2671–2683.Jang I. K., Hursting M. J. When heparins promote thrombosis: review of heparin-induced thrombocytopenia // Circulation. 2005. Vol. 111 (20). P. 2671–2683.Kelton J. G., Warkentin T. E. Heparin-induced thrombocytopenia: a historical perspective // Blood. 2008. Vol. 112 (7). P. 2607–2616.Kelton J. G., Warkentin T. E. Heparin-induced thrombocytopenia: a historical perspective // Blood. 2008. Vol. 112 (7). P. 2607–2616.Lepirudin for anticoagulation in patients with heparininduced thrombocytopenia treated with continuous renal replacement therapy / A. Gajra [et al.] // Am. J. Hematol. 2007. Vol. 82 (5). P. 391–393.Lepirudin for anticoagulation in patients with heparininduced thrombocytopenia treated with continuous renal replacement therapy / A. Gajra [et al.] // Am. J. Hematol. 2007. Vol. 82 (5). P. 391–393.Martel N., Lee J., Wells P. S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis // Blood. 2005. Vol. 106 (8). P. 2710–2715.Martel N., Lee J., Wells P. S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis // Blood. 2005. Vol. 106 (8). P. 2710–2715.Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-a review. Arch. Pathol / F. Fabris [et al.] // Lab. Med. 2000. Vol. 124 (11). P. 1657–1666.Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-a review. Arch. Pathol / F. Fabris [et al.] // Lab. Med. 2000. Vol. 124 (11). P. 1657–1666.Prechel М . М ., Walenga М . J. Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia // Thrombosis Journal. 2013. Vol. 11 (7).Prechel М . М ., Walenga М . J. Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia // Thrombosis Journal. 2013. Vol. 11 (7).Pötzsch B., Klövekorn W. P., Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia // N. Engl. J. Med. 2000. Vol. 343 (7). P. 515.Pötzsch B., Klövekorn W. P., Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia // N. Engl. J. Med. 2000. Vol. 343 (7). P. 515.Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4) / O. Meyer [et al.] // Lancet. 1999. Vol. 354 (9189). P. 1525–1526.Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4) / O. Meyer [et al.] // Lancet. 1999. Vol. 354 (9189). P. 1525–1526.Rhodes G. R., Dixon R. H., Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations // Surg. Gynecol. Obstet. 1973. Vol. 136 (3). P. 409–416.Rhodes G. R., Dixon R. H., Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations // Surg. Gynecol. Obstet. 1973. Vol. 136 (3). P. 409–416.Rice L. Evolving management strategies for heparininduced thrombocytopenia // Semin. Hematol. 2005. Vol. 42 (Suppl 3). P. 15–21.Rice L. Evolving management strategies for heparininduced thrombocytopenia // Semin. Hematol. 2005. Vol. 42 (Suppl 3). P. 15–21.Rivaroxaban an oral, direct Factor Xa inhibitor has potential for the management of patients with heparin-induced thrombocytopenia / J. M. Walenga [et al.] // Br. J. Haematol. 2008. Vol. 143 (1). P. 92–99.Rivaroxaban an oral, direct Factor Xa inhibitor has potential for the management of patients with heparin-induced thrombocytopenia / J. M. Walenga [et al.] // Br. J. Haematol. 2008. Vol. 143 (1). P. 92–99.Roque Pifarre. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997. P. 487–500.Roque Pifarre. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997. P. 487–500.Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) // Thromb. Haemost. 2008. Vol. 99 (4). P. 779–781.Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) // Thromb. Haemost. 2008. Vol. 99 (4). P. 779–781.Shantsila E., Lip G. Y., Chong B. H. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management // Chest. 2009. Vol. 135 (6). P. 1651–1664.Shantsila E., Lip G. Y., Chong B. H. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management // Chest. 2009. Vol. 135 (6). P. 1651–1664.Skin necrosis following subcutaneous heparin injection / A.W. Mar [et al.] // Australas. J. Dermatol. 1995. Vol. 36 (4). P. 201–203.Skin necrosis following subcutaneous heparin injection / A.W. Mar [et al.] // Australas. J. Dermatol. 1995. Vol. 36 (4). P. 201–203.Tapson V. F. Acute pulmonary embolism // N. Engl. J. Med. 2008. Vol. 358 (10). P. 1037–1052.Tapson V. F. Acute pulmonary embolism // N. Engl. J. Med. 2008. Vol. 358 (10). P. 1037–1052.The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia / T. E. Warkentin [et al.] // Ann. Intern. Med. 1997. Vol. 127 (9). P. 804–812.The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia / T. E. Warkentin [et al.] // Ann. Intern. Med. 1997. Vol. 127 (9). P. 804–812.Tomer A., Masalunga C., Abshire T. C. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation // Am. J. Hematol. 1999. Vol. 61 (1). P. 53–61.Tomer A., Masalunga C., Abshire T. C. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation // Am. J. Hematol. 1999. Vol. 61 (1). P. 53–61.Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) / T. E. Warkentin [et al.] // Chest. 2008. Vol. 133 (6 Suppl.). P. 340–380.Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) / T. E. Warkentin [et al.] // Chest. 2008. Vol. 133 (6 Suppl.). P. 340–380.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines / L. Linkins [et al.] // Chest. 2012. Vol. 141 (2 suppl.). P. 495–530.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines / L. Linkins [et al.] // Chest. 2012. Vol. 141 (2 suppl.). P. 495–530.Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia / N. L. Whitlatch [et al.] // Blood. 2010. Vol. 116 (10). P. 1761–1766.Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia / N. L. Whitlatch [et al.] // Blood. 2010. Vol. 116 (10). P. 1761–1766.Warkentin T. E., Greinacher A. So, does low-molecularweight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? // Chest. 2007. Vol. 132 (4). P. 1108–1110.Warkentin T. E., Greinacher A. So, does low-molecularweight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? // Chest. 2007. Vol. 132 (4). P. 1108–1110.Warkentin T. E., Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery // Ann. Thorac. Surg. 2003. Vol. 76 (6). P. 2121–2131.Warkentin T. E., Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery // Ann. Thorac. Surg. 2003. Vol. 76 (6). P. 2121–2131.Warkentin T. E., Kelton J. G. A 14-year study of heparininduced-thrombocytopenia // Am. J. Med. 1996. Vol. 101 (5). P. 502–507.Warkentin T. E., Kelton J. G. A 14-year study of heparininduced-thrombocytopenia // Am. J. Med. 1996. Vol. 101 (5). P. 502–507.Warkentin T. E., Kelton J. G. Temporal aspects of heparin-induced thrombocytopenia // N. Engl. J. Med. 2001. Vol. 344 (17). P. 1286–1292.Warkentin T. E., Kelton J. G. Temporal aspects of heparin-induced thrombocytopenia // N. Engl. J. Med. 2001. Vol. 344 (17). P. 1286–1292.Warkentin T. E., Kelton J. G. Delayed-onset heparininduced thrombocytopenia and thrombosis // Ann. Intern. Med. 2001. Vol. 135 (7). P. 502–506.Warkentin T. E., Kelton J. G. Delayed-onset heparininduced thrombocytopenia and thrombosis // Ann. Intern. Med. 2001. Vol. 135 (7). P. 502–506.Warkentin T. E., Sheppard J. A. Testing for heparininduced thrombocytopenia antibodies» // Transfus. Med. Rev. 2006. Vol. 20 (4). P. 259–272.Warkentin T. E., Sheppard J. A. Testing for heparininduced thrombocytopenia antibodies» // Transfus. Med. Rev. 2006. Vol. 20 (4). P. 259–272.Weismann R. E., Tobin R. W. Arterial embolism occurring during systemic heparin therapy // AMA Arch. Surg. 1958. Vol. 76 (2). P. 219–225 (discussion 225–7).Weismann R. E., Tobin R. W. Arterial embolism occurring during systemic heparin therapy // AMA Arch. Surg. 1958. Vol. 76 (2). P. 219–225 (discussion 225–7).Yeh R. W., Jang I. K. Argatroban: update // Am. Heart J. 2006. Vol. 151 (6). P. 1131–1138.Yeh R. W., Jang I. K. Argatroban: update // Am. Heart J. 2006. Vol. 151 (6). P. 1131–1138.

The authors declare that there are no conflicts of interest present.